Apart from the Revlimid loss, generic price competition in the US, and the addition of new medical representatives in the India business are likely to impact margins this quarter.
Pharma Q3 preview: India growth, base business may offset US headwinds
📅 Published: January 15, 2026 |
📂 Category: Uncategorized
